Activated AKT pathway promotes establishment of endometriosis

Endocrinology

Volumn 155, Issue 5, 2014, Pages 1921-1930

  Kim, Tae Hoon ^a   Yu, Yanni ^b   Luo, Lily ^b   Lydon, John P ^c   Jeong, Jae Wook ^a   Kim, J Julie ^b  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; GLYCOGEN SYNTHASE KINASE 3BETA; PROGESTERONE RECEPTOR; PROTEIN KINASE B; TRANSCRIPTION FACTOR FKHR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; ENDOMETRIOSIS; ENDOMETRIUM; ENDOMETRIUM TUMOR; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN TISSUE; MORPHOLOGY; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION;

ANIMALS; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; CROSSES, GENETIC; DISEASE MODELS, ANIMAL; ENDOMETRIOSIS; ENDOMETRIUM; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; MICE; MICE, TRANSGENIC; OVARIAN DISEASES; OVARY; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; STROMAL CELLS;

EID: 84899455945     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2013-1951     Document Type: Article

References (32)

1. Giudice LC. Clinical practice. Endometriosis. N Engl J Med. 2010; 362:2389-2398.
2. Bulun SE. Endometriosis. N Engl J Med. 2009;360:268-279.
3. Kauppila A, Rönnberg L. Naproxen sodium in dysmenorrhea secondary to endometriosis. Obstet Gynecol. 1985;65:379-383.
4. Crosignani P, Olive D, Bergqvist A, Luciano A. Advances in the management of endometriosis: an update for clinicians. Hum Reprod Update. 2006;12:179-189.
5. Vercellini P, Trespidi L, Colombo A, Vendola N, Marchini M, Crosignani PG. A gonadotropin-releasing hormone agonist versus a low-dose oral contraceptive for pelvic pain associated with endometriosis. Fertil Steril. 1993;60:75-79.
6. Bianchi S, Busacca M, Agnoli B, Candiani M, Calia C, Vignali M. Effects of 3 month therapy with danazol after laparoscopic surgery for stage III/IV endometriosis: a randomized study. Hum Reprod. 1999;14:1335-1337.
7. Child TJ, Tan SL. Endometriosis: aetiology, pathogenesis and treatment. Drugs. 2001;61:1735-1750.
8. Yin X, Pavone ME, Lu Z, Wei JJ, Kim JJ. Increased Activation of the PI3K/AKT pathway compromises decidualization of stromal cells from endometriosis. J Clin Endocrinol Metab. 2012;97:E35-E43.
9. Cinar O, Seval Y, Uz YH, et al. Differential regulation of Akt phosphorylation in endometriosis. Reprod Biomed Online. 2009;19: 864-871.
10. Leconte M, Nicco C, Ngô C, et al. The mTOR/AKT inhibitor temsirolimus prevents deep infiltrating endometriosis in mice. Am J Pathol. 2011;179:880-889.
11. Zhang H, Zhao X, Liu S, Li J, Wen Z, Li M. 17βE2 promotes cell proliferation in endometriosis by decreasing PTEN via NFK{hooktop}B-dependent pathway. Mol Cell Endocrinol. 2010;317:31-43.
12. Velarde MC, Aghajanova L, Nezhat CR, Giudice LC. Increased mitogen-activated protein kinase kinase/extracellularly regulated kinase activity in human endometrial stromal fibroblasts of women with endometriosis reduces 3',5'-cyclic adenosine 5'-monophosphate inhibition of cyclin D1. Endocrinology. 2009;150:4701-4712.
13. Eaton JL, Unno K, Caraveo M, Lu Z, Kim JJ. Increased AKT or MEK1/2 activity influences Progesterone Receptor levels and localization in endometriosis. J Clin Endocrinol Metab. 2013;98:E1871-E1879.
14. Daikoku T, Hirota Y, Tranguch S, et al. Conditional loss of uterine Pten unfailingly and rapidly induces endometrial cancer in mice. Cancer Res. 2008;68:5619-5627.
15. Ryan IP, Schriock ED, Taylor RN. Isolation, characterization, and comparison of human endometrial and endometriosis cells in vitro. J Clin Endocrinol Metab. 1994;78:642-649.
16. Hirai H, Sootome H, Nakatsuru Y, et al. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther. 2010;9:1956-1967.
17. Cantley LC, Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci U S A. 1999;96:4240-4245.
18. Körbel C, Menger MD, Laschke MW. Size and spatial orientation of uterine tissue transplants on the peritoneum crucially determine the growth and cyst formation of endometriosis-like lesions in mice. Hum Reprod. 2010;25:2551-2558.
19. Pelch KE, Schroder AL, Kimball PA, Sharpe-Timms KL, Davis JW, Nagel SC. Aberrant gene expression profile in a mouse model of endometriosis mirrors that observed in women. Fertil Steril. 2010; 93:1615-1627.e18.
20. Umezawa M, Tanaka N, Tainaka H, Takeda K, Ihara T, Sugamata M. Microarray analysis provides insight into the early steps of pathophysiology of mouse endometriosis model induced by autotransplantation of endometrium. Life Sci. 2009;84:832-837.
21. Somigliana E, Viganò P, Rossi G, Carinelli S, Vignali M, Panina- Bordignon P. Endometrial ability to implant in ectopic sites can be prevented by interleukin-12 in a murine model of endometriosis. Hum Reprod. 1999;14:2944-2950.
22. Han SJ, Hawkins SM, Begum K, Jung SY, Kovanci E, Qin J, Lydon JP, DeMayo FJ, O'Malley BW. A new isoform of steroid receptor coactivator-1 is crucial for pathogenic progression of endometriosis. Nat Med. 2012;18:1102-1111.
23. Becker CM, Sampson DA, Short SM, Javaherian K, Folkman J, D'Amato RJ. Short synthetic endostatin peptides inhibit endothelial migration in vitro and endometriosis in a mouse model. Fertil Steril. 2006;85:71-77.
24. BeckerCM,WrightRD,Satchi-Fainaro R, et al.Anovel noninvasive model of endometriosis for monitoring the efficacy of antiangiogenic therapy. Am J Pathol. 2006;168:2074-2084.
25. Olivares C, Ricci A, Bilotas M, Barañao RI, Meresman G. The inhibitory effect of celecoxib and rosiglitazone on experimental endometriosis. Fertil Steril. 2011;96:428-433.
26. Fazleabas AT. A baboon model for inducing endometriosis. Methods Mol Med. 2006;121:95-99.
27. Burns KA, Rodriguez KF, Hewitt SC, Janardhan KS, Young SL, Korach KS. Role of estrogen receptor signaling required for endometriosis-like lesion establishment in a mouse model. Endocrinology. 2012;153:3960-3971.
28. Kim JJ, Buzzio OL, Li S, Lu Z. Role of FOXO1A in the regulation of insulin-like growth factor-binding protein-1 in human endometrial cells: interaction with progesterone receptor. Biol Reprod. 2005;73:833-839.
29. Neubauer NL, Ward EC, Patel P, et al. Progesterone receptor-B induction of BIRC3 protects endometrial cancer cells from AP1- 59-mediated apoptosis. Horm Cancer. 2011;2:170-181.
30. Pant A, Lee II, Lu Z, Rueda BR, Schink J, Kim JJ. Inhibition of AKT with the orally active allosteric AKT inhibitor, MK-2206, sensitizes endometrial cancer cells to progestin. PloS One. 2012;7:e41593.
31. WardEC, Hoekstra AV, Blok LJ, et al. The regulation and function of the forkhead transcription factor, Forkhead box O1, is dependent on the progesterone receptor in endometrial carcinoma. Endocrinology. 2008;149: 1942-1950.
32. Hoekstra AV, Sefton EC, Berry E, et al. Progestins activate the AKT pathway in leiomyoma cells and promote survival. J Clin Endocrinol Metab. 2009;94:1768-1774.